Biossance Doubles Down On 'Free Of' Marketing With Ingredient Blacklist
This article was originally published in The Rose Sheet
Executive Summary
Biossance, the personal-care division of integrated renewable products company Amyris, has unveiled a blacklist of more than 2,000 cosmetic ingredients it "refuses to use" due to safety and environmental concerns. The company discusses its rationale for the move and the controls it has in place in a litigious environment where "free of" claims are under increasing attack.
You may also be interested in...
Amyris Making Headway In Fermentation-Derived Cannabinoids; CBD Could Hit Market In Early 2020
Synthetic biology firm Amyris has shipped to partner Lavvan its first cannabinoid produced via genetically engineered yeast. While Amyris’ announcement does not identify the specific cannabinoid, Lavvan leadership indicated in March 2019 that fermentation-derived CBD would be first to market, representing potential purity and value benefits compared with CBD extracted from the cannabis plant.
Cosmetic News In Brief: Unilever Nabs Living Proof; TINA.org’s ‘Naughty’ List; More
Unilever will add Living Proof hair care to its prestige portfolio through an acquisition expected to close in the 2017 first quarter; Memebox raises $60m in new funding; WEN and The Honest Company make nonprofit Truth In Advertising’s 2016 “naughty” list. More cosmetics news in brief.
PCPSA's 'No Harm' Standard Would Set High Bar For FDA Ingredient Review
Regulatory consultants have concerns about the draft Personal Care Products Safety Act's proposed standard for FDA ingredient review – reasonable certainty of no harm. The standard's de facto application in FDA's review of new dietary ingredients in the supplement space has resulted in a fail rate of around 75%.